SCHEMBL4022865

SCHEMBL4022865

CN(C[C@]1(c2cccc(Cl)c2)C[C@H]1CC=O)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TACR3 P29371 5/20 0.39
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38
SLC6A2 P23975 1/20 0.38
HSD11B1 P28845 1/20 0.38
CCR2 P41597 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTR2C P28335 2/20 0.36
HTR2A P28223 1/20 0.36
HTR2B P41595 1/20 0.36
KDM4E B2RXH2 3/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
OPRK1 P41145 1/20 0.34
AOC3 Q16853 1/20 0.34
TP53 P04637 1/20 0.34
MDM2 Q00987 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021855 1.00 TACR3 (0.39) TACR3SLC6A4SLC6A3SLC6A2HSD11B1
SCHEMBL13720554 0.86 CPB2 (0.38) TACR3SLC6A4SLC6A3SLC6A2HSD11B1
SCHEMBL13721085 0.86 CPB2 (0.38) TACR3SLC6A4SLC6A3SLC6A2HSD11B1
SCHEMBL6172602 0.84 CCR2 (0.36) TACR3SLC6A4SLC6A3SLC6A2HSD11B1
SCHEMBL4022868 0.77 SLC6A4 (0.39) SLC6A4SLC6A3SLC6A2HSD11B1HTR2C
SCHEMBL4021859 0.77 SLC6A4 (0.39) SLC6A4SLC6A3SLC6A2HSD11B1HTR2C
SCHEMBL4020636 0.72 SLC6A2 (0.46) SLC6A4SLC6A3SLC6A2HTR2CKDM4E
SCHEMBL4020339 0.72 SLC6A2 (0.46) SLC6A4SLC6A3SLC6A2HTR2CKDM4E
SCHEMBL4019257 0.71 SLC6A2 (0.39) SLC6A4SLC6A3SLC6A2HTR2COPRK1
SCHEMBL4024571 0.71 SLC6A2 (0.39) SLC6A4SLC6A3SLC6A2HTR2COPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569579-B2 for inhibition of HIV replication and treatment of acquired immune deficiency syndrome SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
EP-1569934-B1 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2008-01-23 EP disclosed
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists SMITHKLINE BEECHAM CORPORATION 2006-03-09 US disclosed
EP-1569934-A2 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004055010-A2 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists CCR5, CCR1, CCL5 TACR3 594/4885SLC6A4 1697/4885SLC6A3 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.